Digestive Cancers Europe shared a post on LinkedIn:
“CME-accredited webinar on HER2 Evolution in Gastroesophageal Cancer.
Discover the most recent evidence on emerging HER2-targeted therapies and their effects on first-line treatment for gastroesophageal adenocarcinoma (GEA). This educational activity aims to help healthcare professionals improve patient outcomes with HER2-positive GEA by applying recent data on the safety and effectiveness of HER2-targeted therapies in practice. It is supported by Digestive Cancers Europe and is available on Medscape.”
Digestive Cancers Europe/LinkedIn
Title: HER2 Evolution in Gastroesophageal Cancer: New Therapies and Optimized Outcomes
Author: Samuel J. Klempner
Read The Full Article on Medscape
More posts featuring Digestive Cancers Europe on OncoDaily.